MSCI recently hosted “OTC Derivatives in Hong Kong: From License to Growth” as part of its Investment Risk Summit series, with support from Sunline, MSCI’s exclusive partner for the event. The summit brought together representatives from the Securities and Futures Commission (SFC), securities firms from Hong Kong, mainland China and other markets, professional advisers and technology providers. Discussions focused on the evolving Type 11 licensing regime and the regulatory, operational and commercial considerations facing firms building OTC derivatives businesses in Hong Kong.
Tom Jenkins, Senior Director, Intermediaries, Securities and Futures Commission, delivered a keynote on supervisory expectations for OTC derivatives. He discussed the framework underpinning the Type 11 regime, the areas supervisors consider as firms prepare for licensing, and the characteristics of a well-structured OTC derivatives operation. Governance, risk management, operational capabilities and internal controls featured prominently in the session.
For firms preparing for the Type 11 regime, starting early provides more time to assess their licensing, governance and operational readiness, and to identify the capabilities that may need to be strengthened.
The panel discussion brought together securities practitioners, professional advisers and technology specialists to examine how firms are approaching Type 11 readiness in practice. The discussion covered preparation timelines, capital considerations, implementation priorities and the business implications of Swap Connect for equity derivatives activities, closely reflecting the practical focus set out in MSCI’s programme. Panellists noted that a comprehensive licensing programme may involve more than 40 regulatory documents and that preparation may take approximately eight to 12 months as established implementation approaches continue to develop. This reinforces the importance of starting early and allocating sufficient time and resources. The discussion also highlighted the need for clear ownership and cross-functional coordination. A CEO-led steering structure, supported by a dedicated project management office, can help align work across front-, middle- and back-office functions and coordinate the end-to-end readiness programme.
Robust data governance is equally important. Firms need consistent, accurate and traceable data to support detailed reporting, risk measurement and day-to-day operations. As Swap Connect and related market access channels continue to develop, Type 11 readiness is increasingly relevant not only to licensing, but also to the ability of Chinese securities firms to expand their cross-border derivatives businesses.
The discussions reinforced that Type 11 readiness is an enterprise-wide undertaking spanning governance, financial management, risk, operations, data and technology. Firms need to coordinate data governance, risk management, trade reporting and operational capabilities to support the long-term development of their OTC derivatives businesses.
Sunline will continue to contribute to industry dialogue and draw on its project experience in Hong Kong’s securities and capital markets industry to support financial institutions in strengthening their OTC derivatives capabilities.
Disclaimer: This article summarises discussions from the event and is provided for general information only. It does not constitute legal, regulatory, investment or other professional advice. Firms should assess the application of any rules or requirements considering their own circumstances and consult legal counsel, professional advisers or relevant authorities where appropriate.
